CellsBin Wins NCI Direct-to-Phase II SBIR for Myeloma Blood Test
Danbury – October 28, 2026 -- CellsBin has received a Direct-to-Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI) to advance CB-Insight, its blood-based test for multiple myeloma, a cancer of plasma cells in the bone marrow.
Federal award follows 108 BioCapital-led Series A
The NCI funding comes after CellsBin's Series A financing, announced in September and led by 108 BioCapital. Together, the private and federal money moves the myeloma program beyond early proof-of-concept work and into formal patient testing and development of a test that can be offered to doctors.
CellsBin first presented early myeloma results at the 2024 American Society of Hematology Annual Meeting. Privately funded work since then made the company eligible for the Direct-to-Phase II track, which lets small businesses that have already shown feasibility skip the Phase I stage.